retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Results: 24% in VisualAbstract: Retatrutide reduces body weight

References Lillys triple G agonist boasts 28.7% weight loss in Phase III trial

Why GLP-1 Agonists

Notably, although there was not a statistically significant increase in biliary disease among GLP-1 receptor agonist users in this study, the FDA 2 added warnings and precautions about acute cholecystitis and biliary disease to the label in late 2022 based on data from placebo-controlled RCTs as well as other observational data 3

We focus on sustainable changes and meeting people where they are. She emphasized that progress matters more than perfection and that long-term success comes from building habits that patients can maintain